medigraphic.com
ISSN 0016-3813 (Print)

2009, Number 2

<< Back Next >>

Gac Med Mex 2009; 145 (2)

Tumores del estroma gastrointestinal. Análisis de factores pronósticos en un grupo de pacientes mexicanos

Medina-Franco H, Aguilar-Jiménez JR, Medina-Cuairán JZ

Language: Spanish
References: 30
Page: 91-96
PDF size: 86.58 Kb.


ABSTRACT

Background: Gastrointestinal stromal tumors (GIST) are uncommon and their prognostic factors remain controversial. The objective of this study was to analyze the clinical and pathological characteristics as well as the prognostic factors of GIST in a sample of Mexican patients.
Methods: We retrospectively analyzed patients admitted with a diagnosis of GIST to a reference center in Mexico between 1997-2007. We analyzed demographic, clinical and histopathological factors of GIST and constructed Kaplan-Meier survival curves which were compared using the log-rank test. Multivariate analysis was performed using the Cox regression test.
Results: Sixty-two patients were included. The most common tumor site was the small bowel (46.8%). Median tumor size was 7.5 cm. The c-kit and p53 immunoanalysis were positive in 92% and 32.3% of cases, respectively. With a median follow-up of 37 months, the 5 year overall survival and disease free survival were 76.05% and 59%, respectively. By univariate analysis, favourable prognostic factors included being female, a low mitotic rate, tumour size ‹10 cm, absence of tumour necrosis and negative immunoreativity for p53; however, only the latter remained significant in the multivariate analysis.
Conclusions: P53 is the strongest prognostic factor independently from mitotic rate or tumour size.


REFERENCES

  1. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12.

  2. Mazur MT, Clark HB. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 1983;7:507-519.

  3. Hirota S, Isosaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain of function of c-KIT in human gastrointestinal stromal tumors. Science 1998;279:577-580.

  4. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the intestinal cells of Cajal. Am J Pathol 1998; 152:1259-1269.

  5. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-465.

  6. Medina-Franco H, Ramos-de la Medina A, Cortés-González R, Baquera J, Ángeles-Ángeles A, Urist MM, et al. Expression of p53 and proliferation index as prognostic factors in gastrointestinal sarcomas. Ann Surg Oncol 2003; 10:190-195.

  7. Heslin MJ, Cordon-Cardo C, Lewis JJ, Woodruff JM, Brennan MF. Ki67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high-grade extremity soft tissue sarcoma. Cancer 1998;83:490-497.

  8. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.

  9. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progresion-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial. Lancet 2004;364:1127-1134.

  10. Rankin C, VonMehren M, Blanke C, Benjamin R, Fletcher CDM, Bramwell V, et al. Dose effect of imatinib in patients with metastatic GIST-Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol 2004;22: Abstract 9005.

  11. Nilsson B, Sjölund K, Kindblom LG, Meis-Kindblom JM, Blümming P, Nilsson O, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high risk gastrointestinal stromal tumours. Br J Cancer 2007;96:1656-1658.

  12. DeMatteo RP, Owzer K, Maki R, Pisters P, Blackstein M, Antonescu C, et al. Gleevec decreases cancer recurrence for patients with primary gastrointestinal stromal tumor. Procs Am Soc Clin Oncol 2007;25: Abstract 10079.

  13. Alvarado-Cabrero I, Vázquez G, Sierra-Santiesteban FI, Hernández- Hernández DM, Zavala-Pompa A. Clinicopathologic study of 275 cases of gastrointestinal stromal tumors: the experience at 3 large medical centres in Mexico. Ann Diagn Pathol 2007;11:39-45.

  14. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.

  15. Medina-Franco H, Eltoum I, Urist MM, Heslin MJ. Primary gastrointestinal sarcomas. Am Surg 2000;66:1171-1175.

  16. Orosz Z, Tornoczky T, Sapi Z. Gastrointestinal stromal tumors: a clinicopathologic and immunohistochemical study of 136 cases. Pathol Oncol Res 2005;11:11-21.

  17. Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol 2006;23:120-129.

  18. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002; 33:478-483.

  19. Medina-Franco H, Heslin MJ, Cortés-González R. Clinicopatological characteristics of gastric carcinoma in young and elderly patients: a comparative study. Ann Surg Oncol 2000;7:515-519.

  20. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83.

  21. DeMatteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG, et al. Tumor mitotic rate, size and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008;112:605-615.

  22. Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, et al. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer 2006; 106:1617-1623.

  23. Gumurdulu D, Erdogan S, Kayaselcuk F, Seydaoglu G, Parsak CK, Demircan O, et al. Expression of COX-2, PCNA, Ki-67 and p53 in gastrointestinal stromal tumors and its relationship with histopathological parameters. World J Gastroenterol 2007;13:426-431.

  24. Martínez-Consuegra N, Baquera-Heredia J, de León-Bojorge B, Padilla- Rodríguez A, Hidalgo CO. Expression of p53 and Bcl-2 as prognostic markers and for anatomical location in gastrointestinal stromal tumors (GIST). Clinico-pathological and immunohistochemical study of 19 cases. Rev Gastroenterol Mex 2006;71:269-278.

  25. Hata Y, Ishigami S, Natsugoe S, Nakajo A, Okumura H, Miyazono F, et al. p53 and MIB-1 expression in gastrointestinal stromal tumors of the stomach. Hepatogastroenterology 2006;53:613-615.

  26. Al-Bozom IA. P53 expression in gastrointestinal stromal tumors. Pathol Int 2001;51:519-523.

  27. Wang Q, Kou YW. Study of the expression of p53 and bcl-2 genes, and the telomerase activity and apoptosis in GIST patients. World J Gastroenterol 2007;13:2626-2628.

  28. Meara RS, Cangarella J, Simsir A, Horton D, Eltoun I, Chhieng DC. Prediction of aggressiveness of gastrointestinal stromal tumors based on immunostaining with bcl-2, Ki-67 and p53. Cytopathology 2007;18:283-289.

  29. Van der Vijver MJ, He YD, van´t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Eng J Med 2002;347:1999-2009.

  30. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expresion and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol 2006;24:3726-3734.




2020     |     www.medigraphic.com